A healthcare-themed salon event was held at the Yichuang Advanced Technology Industrial Park in Beijing E-Town on Mar 30.

Representatives of healthcare enterprises and investment institutions participate in the salon event. [Photo/beijingetown.com.cn]

Several healthcare enterprises in the area gathered to share their latest research and development progress and financing plans. Among them, some companies are expected to launch multiple products this year, further activating the vitality of the healthcare industry in Beijing E-Town and promoting the industrialization process.

During the event, enterprises LAMH (Laboratory for Advanced Medicine & Health Group), Beijing Neoletix Biological Technology, Beijing NeuroCare Medical Co and other healthcare companies conducted roadshows.

A representative introduces her investment company. [Photo/beijingetown.com.cn]

Support policies for healthcare industries are discussed. [Photo/beijingetown.com.cn]

LAMH has the earliest accumulation of methylation technology in the world and has the world's largest sample library of over 300,000 in China and over 30,000 in the United States. It takes the lead in the field of cancer early screening and diagnosis in the world. 

Currently, the company has crossed the development watershed, completed the strategic layout of multiple cancers, and is simultaneously developing eight products, including technology to screen single cancers, stomach cancers, colon cancers, lung cancers, and esophageal cancers. 

"Among them, NGS products for six cancers, 22 cancers, and three single cancers are expected to be launched this year," said the representative of LAMH. 

The company will soon settle in a new research and development center, doubling in size and continuing to focus on the development of more early screening and diagnosis products for cancer, according to sources.

Another enterprise in Beijing E-Town, Beijing NeuroCare Medical Co, has focused on intervention treatment for cerebrovascular disease for many years. 

Based on the framework of the dual-core products of thrombus retrieval stent and dense mesh stent, the company has accumulated over 20 independent research and development product pipelines, covering four major product series of intracranial ischemic stroke, intracranial hemorrhagic stroke, intracranial stenosis, and intracranial passage. The company has completed a comprehensive layout in the field of stroke indications. 

"Our research and development have achieved significant results, and we have entered the stage of intensive product certification," said the representative of Beijing NeuroCare Medical Co.

The enterprise now has obtained NMPA approval for seven products, and another three new products are expected to be launched this year.

After the roadshow, Fang Dalong, executive partner of GGV Capital, and Li Hao, an official of the Yizhuang Talent Innovation and Entrepreneurship Development Center, shared their views on "The Investment Trend and Logic of the Medical Industry in 2023" and "Promoting Industry-Talent Integration." 

After that, entrepreneurs and investors at the event conducted a roundtable discussion on "Which technologies can become platform-based technologies in the future".